Anthony Manouk - Cannara Biotech VP GM
| LOVE Stock | CAD 0.68 0.01 1.49% |
Insider
Anthony Manouk is VP GM of Cannara Biotech
| Address | 333 Decarie Blvd., Saint-Laurent, QC, Canada, H4N 3M9 |
| Phone | 514 543 4200 |
| Web | https://cannara.ca |
Cannara Biotech Management Efficiency
The company has return on total asset (ROA) of 0.0378 % which means that it generated a profit of $0.0378 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0678 %, meaning that it generated $0.0678 on every $100 dollars invested by stockholders. Cannara Biotech's management efficiency ratios could be used to measure how well Cannara Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to 0.05 in 2024. Return On Capital Employed is likely to climb to 0.09 in 2024. At this time, Cannara Biotech's Intangible Assets are fairly stable compared to the past year. Return On Tangible Assets is likely to climb to 0.05 in 2024, whereas Net Tangible Assets are likely to drop slightly above 50.7 M in 2024.Similar Executives
| Found 11 records | INSIDER Age | ||
| Melanie Ramsey | Rubicon Organics | N/A | |
| Peter Dierx | Rubicon Organics | N/A | |
| Jesse MA | Rubicon Organics | 47 | |
| Yannick Poulin | Lion Electric Corp | 42 | |
| Nathalie Giroux | Lion Electric Corp | 48 | |
| Brian Piern | Lion Electric Corp | 55 | |
| Marc Bedard | Lion Electric Corp | 60 | |
| Francois Duquette | Lion Electric Corp | 51 | |
| Benoit Pinsonneault | Rubicon Organics | N/A | |
| Francois Beaulieu | Lion Electric Corp | N/A | |
| Patrick Gervais | Lion Electric Corp | N/A | |
Management Performance
| Return On Equity | 0.0678 | ||||
| Return On Asset | 0.0378 |
Cannara Biotech Leadership Team
Elected by the shareholders, the Cannara Biotech's board of directors comprises two types of representatives: Cannara Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cannara. The board's role is to monitor Cannara Biotech's management team and ensure that shareholders' interests are well served. Cannara Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cannara Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Abitbol, Vice Marketing | ||
| France Landry, Vice Resources | ||
| Zohar Krivorot, CEO Chairman | ||
| Avi Krivorot, Chief Officer | ||
| Scott Carroll, Vice Sales | ||
| Anthony Manouk, VP GM | ||
| Brian Sherman, General Affairs | ||
| Julia Bouvet, Chief Staff | ||
| Etienne Ledoux, Executive Officer | ||
| Alexander Wolfe, VP Devel |
Cannara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cannara Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cannara Stock Analysis
When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.